Executive Leadership

Partnership: It’s what turns services into solutions

Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Executive Chairman, Board of Directors
Song Li, Ph.D.

Song Li, Ph.D.

Executive Chairman, Board of Directors

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

linkedin logo 150x150 - Song Li, Ph.D.

 

Read Full Bio
Andrew Wang

Andrew Wang

Chief Financial Officer (CFO)
Andrew Wang

Andrew Wang

Chief Financial Officer (CFO)

Mr. Wang has more than 27 years of extensive experience in financial service and accounting aspect, include corporate finance and treasury management, corporate accounting, compliance, internal control and corporate budgetary management. Mr. Wang is the Chief Financial Officer of the Company and is responsible for the management of all aspects of the Group’s finance and treasury matters.  Prior to joining Frontage in October 2020, Mr. Wang was the Chief Financial Officer of Frontida Biopharm, Inc., a contract development and manufacturing organization in the United States of America. Previously, he was the Chief Financial Officer and the Director of the Board of Sky Solar Holdings, Ltd. a NASDAQ listed company.  Before that, he served as finance director or controller in different multinational companies, mainly in the Asia Pacific area.

 

Mr. Wang is a professional accountant, having been a member of the China Institute of Certified Public Accountant since August 1995.  Mr. Wang was awarded an Executive Master of Business Administration by Washington University in St. Louis in December 2004.  In July 1993, he was awarded a Bachelor’s degree in Accounting by University of Shanghai for Science and Technology.

linkedin logo 150x150 - Andrew Wang

Read Full Bio
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Chief Executive Officer, Frontage Laboratories, Inc.
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Chief Executive Officer, Frontage Laboratories, Inc.

Dr. Abdul Mutlib is the Chief Executive Officer at Frontage Laboratories, Inc. Before this, he was the Global Head of DMPK/Preclinical Services and led operations for these services. Prior to joining Frontage in 2010, he held director-level roles within drug metabolism teams at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel and DuPont-Merck.  With more than 20 years of experience in drug metabolism and analytical chemistry, Dr. Mutlib’s research includes the application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty papers in peer-reviewed journals.

Dr. Mutlib earned a bachelor’s degree in pharmacy and a doctor of philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships from the Universities of Washington and British Columbia.

linkedin logo 150x150 - Abdul Mutlib, Ph.D.

Read Full Bio
John Lin, Ph.D.

John Lin, Ph.D.

President, Frontage Laboratories, Inc.
John Lin, Ph.D.

John Lin, Ph.D.

President, Frontage Laboratories, Inc.

Dr. John Lin is the President of Frontage Laboratories, Inc. Before this, he served as the Executive Vice President, Bioanalytical and Biologics Services, where he led operations for the company’s global bioanalytical labs. Before joining Frontage, he served as a business leader in AstraZeneca’s global drug metabolism and pharmacokinetics (DMPK) division. Prior to AstraZeneca, Dr. Lin was Laboratory Director for Avantix Laboratories.

With more than 20 years of experience, Dr. Lin’s current research focus is in the area of bioanalytical method development and validation, dry blood spot (DBS) sampling with LC-MS/MS analysis, and biomarker quantification using LC-MS/MS. He has contributed to more than 20 research publications covering the development and validation of LC-MS/MS methods for the determination of small and large molecules in biological matrices, four book chapters, and one technical patent. He is the invited reviewer for several international journals including the Journal of Pharmaceutical Biomedical Analysis (JPBA) and the Journal of Chromatography B (JCB).

Dr. Lin earned a doctor of philosophy degree in analytical chemistry from Dalhousie University in Canada. He received a master’s degree in analytical chemistry from Yunnan University and a bachelor of science degree in chemistry from Fuzhou Branch School of Jiangxi Normal College. Dr. Lin completed post-doctoral research in pharmacokinetics and metabolism at the College of Pharmacy and the Comprehensive Cancer Center of the Ohio State University.

linkedin logo 150x150 - John Lin, Ph.D.

Read Full Bio
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services

With more than 20 years of pharmaceutical and biotech industrial experience, Dr. Wang is responsible for the Global CMC (Chemistry Manufacturing & Control) Services at Frontage, including analytical services, formulation development, and manufacturing of GLP preclinical tox batches & GMP clinical trial materials. Products include oral formulations, topical and sterile injections & ophthalmic formulations for IND, NDA, and ANDA filings. Prior to joining Frontage in February 2007, Dr. Wang served as the director of Analytical Chemistry at NovaDel Pharma Inc., where she led teams providing support for NDA product development, clinical supply manufacturing, CMC sections of 505(b)(2) filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed Pharmaceutical Analysis and Control department at Therics Inc. to support 3D printing product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.

Dr. Wang earned her Ph.D. in Chemistry from Iowa State University, followed by postdoctoral research at the University of Chicago. She received her MS in Chemical Engineering from China Institute of Atomic Energy and a BS in Chemistry from Peking University in China.

linkedin logo 150x150 - Dongmei Wang, Ph.D.

Read Full Bio
Wentao Zhang, Ph.D.

Wentao Zhang, Ph.D.

Executive Vice President of Frontage West Coast Operations
Wentao Zhang, Ph.D.

Wentao Zhang, Ph.D.

Executive Vice President of Frontage West Coast Operations

Dr. Wentao Zhang is the Executive Vice President of Frontage West Coast Operations and leads its efforts in Discovery Services. Dr. Zhang joined Frontage in 2021 through the acquisition of Quintara Discovery, a drug discovery service company he founded in the San Francisco Bay Area in 2012. Before founding Quintara, Dr. Zhang was Senior Director of New Lead Discovery at Exelixis of South San Francisco where he managed key drug discovery platforms and functions that included compound repository, assay development and high-throughput screening, lead optimization, DMPK operations, and safety pharmacology. 

Dr. Zhang made significant contributions to over twenty compounds from discovery that advanced to clinical development, including the discovery, in vitro ADME and pharmacological characterizations of two FDA-approved small molecule drugs. Dr. Zhang has been an ad hoc member of the NIH study section on assay development & HTS. He has authored and co-authored discovery data packages (biology) and preclinical DMPK study reports for IND and NDA filings, as well as over thirty scientific publications. Dr. Zhang received his Ph.D. in biophysical chemistry from the University of Wisconsin-Madison and his B.S. in Chemistry from Peking University. He has also conducted research in the area of DNA replication as a postdoctoral fellow at the University of California-Berkeley.

Read Full Bio
Lisa Diamond, Ph.D.

Lisa Diamond, Ph.D.

President, Frontage Clinical Services
Lisa Diamond, Ph.D.

Lisa Diamond, Ph.D.

President, Frontage Clinical Services

As President of Frontage Clinical Services since 2018, Dr. Diamond leads operations for the US Clinical service group. Dr. Diamond joined Frontage as Director of Clinical Affairs in 2005, and manages cross-functional teams, including Data Management, Programming, Biostatistics, Project Management and Medical Writing, provides Clinical Operations oversight and supports Business Development and Client Relations. Her prior positions in academia, small biopharmaceutical companies, and at Bristol-Myers Squibb contribute to a broad experience base in research and development, and preclinical and clinical research.

Dr. Diamond earned a Doctor of Philosophy and Master of Science degrees in Basic Medical Sciences from New York University (New York, NY), and a Bachelor of Science degree in Biology from Suffolk University (Boston, MA). She completed post-doctoral training at Princeton University (Princeton, NJ), and is an adjunct professor at Rider University (Lawrenceville, NJ).

linkedin - Lisa Diamond, Ph.D.

Read Full Bio
Yining Qi, MBA

Yining Qi, MBA

President, Frontage's China Operations
Yining Qi, MBA

Yining Qi, MBA

President, Frontage's China Operations

Before joining Frontage, Dr Qi served as Vice President of R&D, RA and Medical and President of research institute for Hebei Changshan Biochemical Pharmaceutical Company Inc.  Prior to that, he was global Senior VP of Operation & General Manager (Taicang) of Crown Bioscience Inc. and served as Board Chairman and General Manager of Taicang-Crownbio Biopharmaceutical Analysis, Inc. Dr. Qi has held several other notable roles including: Executive Director of Technical Operation, Client Services and Project Management of WuXi AppTec (Suzhou) Co., Ltd.; Research Fellow, Group Leader, Laboratory Technical Operations (LTO) Safety Assessment of Merck Research Laboratories (MRL); Sr. Clinical Project Manager/DBA of Becton, Dickinson and Company; Director of Department of Toxicology and Pharmacology, Beijing Institute for Drug Control of NMPA Beijing Branch.                                  

Dr. Qi received a Master of Business Administration in Pharmaceutical Management from Rutgers University in 2007, a Master of Science in Computer Science from Southeastern University in 1999, a Master of Public Health from Shanxi Medical University in 1991, and a Bachelor of Medicine (M.D. equivalent) from Shanxi Medical University in 1984.                                                                

“It’s my great honor and pleasure to join Frontage,” said Dr. Qi. “I believe that my past R&D and management experience will further help to enhance Frontage’s ability to provide high quality and efficient service for pharmaceutical companies and R&D institutions.”

Read Full Bio
Richard Fischetti

Richard Fischetti

Vice President and General Counsel
Richard Fischetti

Richard Fischetti

Vice President and General Counsel

Richard Fischetti, Vice President and General Counsel, has extensive experience in corporate law relating to life sciences companies.  Prior to joining Frontage, Richard was a Partner in the Mergers & Acquisitions Group of Shearman & Sterling LLP, a multinational law firm headquartered in New York City, where he practiced for over a decade.  While at Shearman, Richard led numerous strategic transactions for both public and private companies, including mergers, acquisitions and joint ventures,  as well as advising on matters related to securities laws, corporate governance and shareholder activism.  Much of his experience involved advising various life sciences companies.

 

Richard earned his BA with highest honors and JD with high honors from Rutgers University.

Read Full Bio
Suden Rao, Ph.D.

Suden Rao, Ph.D.

Senior Vice President, Human Resources, North America
Suden Rao, Ph.D.

Suden Rao, Ph.D.

Senior Vice President, Human Resources, North America

Dr. Sudendra (Suden) Rao joins Frontage as Senior Vice President, Human Resources, North America. In this new role, Suden will be leading the HR teams across all of Frontage’s North American sites.

His broad mandate will be to lead the transition of our HR team to an expanded organization, scaled to meet the growing needs of our rapidly growing businesses. Working closely and collaboratively with the business units and other functional support groups, his primary areas of focus will be implementation of HR best practices, processes, and systems in the areas of employee recruiting, training and development, retention and engagement.

Suden brings over 25 years of US and global human resources leadership experience with entrepreneurial startup to world-class Fortune 500 organizations. Suden has worked with pharmaceutical, biotechnology, CRO, medical devices and healthcare organizations known for HR best practices and recognized among the Best Companies to Work For. Most recently he was the Chief HR Officer of Cadila Pharmaceuticals, supporting operation, transformation, and exponential growth across Americas, EMEA and Asia. Previously he has held US and global HR leadership roles at DaVita and Quest Diagnostics, both Fortune 500 healthcare leaders, where he successfully led organizational restructuring, change management and automation and digital transformation of HR, supporting organic and M&A growth.

Suden received a PhD in HRD from the Colorado State University, USA and MA in Economics and Bachelor’s in Law from India, and a Gold Medal in Training and Development. He is a frequently invited speaker at international HR and business forums.

 

linkedin logo 150x150 - Suden Rao, Ph.D.

Read Full Bio
Jeffrey Yablon

Jeffrey Yablon

Senior Vice President, Operations
Jeffrey Yablon

Jeffrey Yablon

Senior Vice President, Operations

Jeff Yablon has over 30 years of international business leadership experience in strategic planning, P&L management, and BD/sales/marketing in both pharmaceutical and CRO companies. Prior to joining Frontage, Jeff was a senior executive at several well-known industry participants, including Icon Plc., BARC, Abbott Laboratories, Parexel, and Cognizant Technology Solutions, and was also the founder of a CRO business in Asia.  In addition, Jeff was on the faculty of The Stony Brook University, Center for Biotechnology, where he lectured on clinical development and the “Business of Bioscience.”  He has also lectured at several universities in Asia.

Jeff received a BA degree from Stockton University and an Executive MBA in International Business Management from Fairleigh Dickinson University.

linkedin - Jeffrey Yablon

Read Full Bio